The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The company announced positive topline data from the Phase 3 ADorable-1 trial
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
The trial will enroll up to 42 patients in Finland across four cohorts
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Subscribe To Our Newsletter & Stay Updated
